社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
励晶太平洋(00575)
0.700
-0.030
-4.11%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
月儿圆风儿轻
·
03-31 23:04
$励晶太平洋(00575)$
AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。
$励晶太平洋(00575)$AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，...
回复
评论
点赞
1
编组 21备份 2
分享
举报
月儿圆风儿轻
·
03-31 23:03
$励晶太平洋(00575)$
这产品前景挺明朗，市场需求也够扎实，毕竟瞄准的是刚需赛道。路演的时候感觉管理层经验老道，执行力看着够强，之前做业务拓展也有实打实的成功案例。不过公司路演里的市场模型和估值假设（像市盈率、市净率这些）偏激进，后续还得靠关键里程碑的落地，才能慢慢强化市场对它估值的信心。
$励晶太平洋(00575)$这产品前景挺明朗，市场需求也够扎实，毕竟瞄准的是刚需赛道。路演的时候感觉管理层经验老道，执行力看着够强，之前做业务拓展也有实打...
回复
评论
点赞
1
编组 21备份 2
分享
举报
外星人攻占我司
·
03-31 23:00
$励晶太平洋(00575)$
AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。
$励晶太平洋(00575)$AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，...
回复
评论
点赞
1
编组 21备份 2
分享
举报
学不到很多
·
03-31 21:30
$励晶太平洋(00575)$
翻了下公司历史，励景其实挺大方的，累计给股东返了2.98亿美元，其中光股息就有2.393亿，还有5960万的股票回购。近年没派息也正常，钱都砸在开发临床和市场拓展上了，总结就是一切都等商业化。其实deep longevity在香港印度都已经签了大客户，按部就班搞问题不大
$励晶太平洋(00575)$ 翻了下公司历史，励景其实挺大方的，累计给股东返了2.98亿美元，其中光股息就有2.393亿，还有5960万的股票回购。近年没...
回复
评论
点赞
1
编组 21备份 2
分享
举报
发活动地点
·
03-31
$励晶太平洋(00575)$
现在这药在欧洲已经获批的国家里都不够卖！这玩意儿跟消费品逻辑挺像，供给决定需求，一旦获批，供给一跟上，销量肯定能跟着往上冲，到时候特许权使用费也得跟着涨
$励晶太平洋(00575)$ 现在这药在欧洲已经获批的国家里都不够卖！这玩意儿跟消费品逻辑挺像，供给决定需求，一旦获批，供给一跟上，销量肯定能跟着往上冲，...
回复
评论
点赞
1
编组 21备份 2
分享
举报
大风车吹吹
·
02-08
$励晶太平洋(00575)$
现在的年轻群体对男性健康问题一点不避讳，认知上来了，主动关注和用药的人自然越来越多，再加上线上购药越来越普及，隐私性好还方便，正规处方药慢慢把乱七八糟的偏方和不合规产品挤出去是板上钉钉的事，手里有海外获批成熟品种的公司，天然就有合规和临床数据的硬壁垒
$励晶太平洋(00575)$
$复星医药(600196)$
$泰恩康(301263)$
$励晶太平洋(00575)$ 现在的年轻群体对男性健康问题一点不避讳，认知上来了，主动关注和用药的人自然越来越多，再加上线上购药越来越普及，隐私性好还方便...
回复
评论
点赞
1
编组 21备份 2
分享
举报
肯帕杜听了吗
·
02-08
$励晶太平洋(00575)$
长寿科技赛道已从概念走向实质落地，毕马威数据显示2035年中国抗衰老产业规模将触及4.6万亿元，2024-2035年复合增速19.8%，是整体医疗健康增速的3.9倍。高净值人群前置健康投资需求持续爆发，调研显示超33.8%的高净值人群主动增加抗衰与健康管理支出，定制化延寿服务与AI量化评估成为两大核心增长点。
$励晶太平洋(00575)$
$中基长寿科学(00767)$
$雅本化学(300261)$
$励晶太平洋(00575)$ 长寿科技赛道已从概念走向实质落地，毕马威数据显示2035年中国抗衰老产业规模将触及4.6万亿元，2024-2035年复合增速...
回复
评论
点赞
1
编组 21备份 2
分享
举报
锦龙
·
02-07
$励晶太平洋(00575)$
国家级专精特新“小巨人”康诺生物冲刺港股！以线粒体医学为核心，搭建“检测-干预-再检测”完整闭环，核心产品占营收半壁江山，两款管线进入临床二期，叠加抗衰赛道高景气，成长逻辑清晰可落地
$励晶太平洋(00575)$
$石药集团(01093)$
$励晶太平洋(00575)$ 国家级专精特新“小巨人”康诺生物冲刺港股！以线粒体医学为核心，搭建“检测-干预-再检测”完整闭环，核心产品占营收半壁江山，两...
回复
评论
点赞
1
编组 21备份 2
分享
举报
一共是
·
02-07
$励晶太平洋(00575)$
低估值、有实控业务、有催化节点的标的值得高看一眼，
$励晶太平洋(00575)$
的药品业务托底、AI 长寿业务提估值，
$中基长寿科学(00767)$
的服务端稳需求，两个都属于被情绪低估的品种。$平安好医生$ 回调到位，$阿里健康$还行吧，再跟进看看
$励晶太平洋(00575)$ 低估值、有实控业务、有催化节点的标的值得高看一眼，$励晶太平洋(00575)$ 的药品业务托底、AI 长寿业务提估值， $中...
回复
评论
点赞
1
编组 21备份 2
分享
举报
落叶松有空
·
02-07
$励晶太平洋(00575)$
的Senstend(Fortacin)早已在欧洲多国获批商业化，外用早泄喷剂赛道海外布局成熟！现在复星万邦助力冲刺中国市场，国内5500万20-59岁男性早泄潜在患者、首年900万潜在用户，空间远超海外。700万确定性里程碑付款更是业绩安全垫，估值修复逻辑硬得很！
$励晶太平洋(00575)$ 的Senstend(Fortacin)早已在欧洲多国获批商业化，外用早泄喷剂赛道海外布局成熟！现在复星万邦助力冲刺中国市场，...
回复
评论
点赞
1
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
励晶太平洋
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.Regentpac.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
励晶太平洋集团有限公司（原名：寿康集团有限公司）是一家主要从事生物医药及投资业务的投资控股公司。该公司通过两个分部运营业务。生物医药分部主要从事生物医药产品的研究、开发、制造、推广及销售业务。企业投资分部主要从事上市及非上市公司投资业务。该公司还从事衰老研究及开发衰老研究相关的人工智能模型和工具产品。其向长寿诊所、预防医学组织、健康俱乐部、保险公司和老化研究机构提供老化和长寿时钟。
03-26
年度报告
截至二零二五年十二月三十一日止年度之经审核末期业绩
截至二零二五年十二月三十一日止年度之经审核末期业绩
2025-09-22
半年度报告
2025中期报告
2025中期报告
2025-08-27
半年度报告
截至二零二五年六月三十日止六个月之未经审核中期业绩
截至二零二五年六月三十日止六个月之未经审核中期业绩
2025-06-25
股份发行
完成关连交易 - 涉及根据特别授权发行新股份之贷款资本化
完成关连交易 - 涉及根据特别授权发行新股份之贷款资本化
2025-05-15
股份发行
(1)关连交易 - 涉及根据特别授权发行新股份之贷款资本化及(2)股东特别大会通告
(1)关连交易 - 涉及根据特别授权发行新股份之贷款资本化及(2)股东特别大会通告
2025-04-28
股份购回
(1)建议发行股份及回购股份之一般授权；(2)重选退任董事；及(3)股东周年大会通告
(1)建议发行股份及回购股份之一般授权；(2)重选退任董事；及(3)股东周年大会通告
2025-04-28
年度报告
2024年年报
2024年年报
2025-04-07
股份发行
关连交易 - 涉及根据特别授权发行新股份之贷款资本化
关连交易 - 涉及根据特别授权发行新股份之贷款资本化
2025-03-27
年度报告
截至二零二四年十二月三十一日止年度之经审核末期业绩
截至二零二四年十二月三十一日止年度之经审核末期业绩
2025-02-04
业绩预告
截至二零二四年十二月三十一日止年度之业绩预告
截至二零二四年十二月三十一日止年度之业绩预告
2024-09-23
半年度报告
2024中期报告
2024中期报告
2024-08-28
半年度报告
截至二零二四年六月三十日止六个月之未经审核中期业绩
截至二零二四年六月三十日止六个月之未经审核中期业绩
2024-07-25
业绩预告
二零二四年半年度业绩预告
二零二四年半年度业绩预告
2024-07-02
须予披露的交易
终止有关出售目标公司之25%股权之须予披露交易
终止有关出售目标公司之25%股权之须予披露交易
2024-06-14
须予披露的交易
须予披露交易 - 出售上市证券
须予披露交易 - 出售上市证券
分时
5日
日
周
月
数据加载中...
最高
0.700
今开
0.700
量比
0.51
最低
0.700
昨收
0.730
换手率
0.01%
热议股票
{"pagemeta":{"title":"励晶太平洋(00575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供励晶太平洋(00575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"励晶太平洋,00575,励晶太平洋股票,励晶太平洋股票老虎,励晶太平洋股票老虎国际,励晶太平洋行情,励晶太平洋股票行情,励晶太平洋股价,励晶太平洋股市,励晶太平洋股票价格,励晶太平洋股票交易,励晶太平洋股票购买,励晶太平洋股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"励晶太平洋(00575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供励晶太平洋(00575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"00575","data":{"stockData":{"symbol":"00575","market":"HK","secType":"STK","nameCN":"励晶太平洋","latestPrice":0.7,"timestamp":1775117299435,"preClose":0.73,"halted":0,"volume":20000,"delay":0,"changeRate":-0.04109589041095894,"floatShares":292000000,"shares":292000000,"eps":-0.14107356986668546,"marketStatus":"耶稣受难节休市","change":-0.03,"latestTime":"04-02 16:08:19","open":0.7,"high":0.7,"low":0.7,"amount":14000,"amplitude":0,"askPrice":0.73,"askSize":100000,"bidPrice":0.67,"bidSize":70000,"shortable":0,"etf":0,"ttmEps":-0.9875149890667982,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":7,"adr":0,"listingDate":863971200000,"exchange":"SEHK","adjPreClose":0.73,"openAndCloseTimeList":[[1775093400000,1775102400000],[1775106000000,1775116800000]],"volumeRatio":0.5146945294594351,"lotSize":10000,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.548642772480288","cardData":[{"tweetId":"548642772480288","author":{"authorId":"4238066285514802","idStr":"4238066285514802","name":"月儿圆风儿轻","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$</a>AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。","plainDigest":"$励晶太平洋(00575)$AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1774969469559,"gmtModify":1774969832261,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":34,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548642772480288","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":287,"displayRows":4,"foldSize":0,"authorId":"4238066285514802"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.548642443771920","cardData":[{"tweetId":"548642443771920","author":{"authorId":"4238066285514802","idStr":"4238066285514802","name":"月儿圆风儿轻","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$</a>这产品前景挺明朗，市场需求也够扎实，毕竟瞄准的是刚需赛道。路演的时候感觉管理层经验老道，执行力看着够强，之前做业务拓展也有实打实的成功案例。不过公司路演里的市场模型和估值假设（像市盈率、市净率这些）偏激进，后续还得靠关键里程碑的落地，才能慢慢强化市场对它估值的信心。","plainDigest":"$励晶太平洋(00575)$这产品前景挺明朗，市场需求也够扎实，毕竟瞄准的是刚需赛道。路演的时候感觉管理层经验老道，执行力看着够强，之前做业务拓展也有实打实的成功案例。不过公司路演里的市场模型和估值假设（像市盈率、市净率这些）偏激进，后续还得靠关键里程碑的落地，才能慢慢强化市场对它估值的信心。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1774969386362,"gmtModify":1774969831766,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":83,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548642443771920","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":273,"displayRows":4,"foldSize":0,"authorId":"4238066285514802"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.548641455530248","cardData":[{"tweetId":"548641455530248","author":{"authorId":"4218631187267610","idStr":"4218631187267610","name":"外星人攻占我司","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$</a>AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。","plainDigest":"$励晶太平洋(00575)$AI医疗赛道，B2B2C的模式效率是最高的。通过产品不断优化、数据越积越多，在根本上拉开和同行的技术差距。技术壁垒一旦做起来，面对企业、保险公司这些大客户，议价权就会变强，比如衰老指标检测得更精准，就能支撑更高的订阅定价，同时也把行业门槛拉高了，后面的竞争对手很难复制它的数据和算法优势。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1774969234277,"gmtModify":1774969831694,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":31,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548641455530248","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":287,"displayRows":4,"foldSize":0,"authorId":"4218631187267610"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.548619348993776","cardData":[{"tweetId":"548619348993776","author":{"authorId":"4163742034225800","idStr":"4163742034225800","name":"学不到很多","avatar":"https://static.tigerbbs.com/40f60ad5332d46bdd16fb13c96b360cb","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 翻了下公司历史，励景其实挺大方的，累计给股东返了2.98亿美元，其中光股息就有2.393亿，还有5960万的股票回购。近年没派息也正常，钱都砸在开发临床和市场拓展上了，总结就是一切都等商业化。其实deep longevity在香港印度都已经签了大客户，按部就班搞问题不大","plainDigest":"$励晶太平洋(00575)$ 翻了下公司历史，励景其实挺大方的，累计给股东返了2.98亿美元，其中光股息就有2.393亿，还有5960万的股票回购。近年没派息也正常，钱都砸在开发临床和市场拓展上了，总结就是一切都等商业化。其实deep longevity在香港印度都已经签了大客户，按部就班搞问题不大","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1774963823521,"gmtModify":1774963826166,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":80,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548619348993776","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":252,"displayRows":4,"foldSize":0,"authorId":"4163742034225800"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.548308016691176","cardData":[{"tweetId":"548308016691176","author":{"authorId":"4163739437225380","idStr":"4163739437225380","name":"发活动地点","avatar":"https://static.tigerbbs.com/62d61add2dc45a0f7c0c63eef3a79583","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 现在这药在欧洲已经获批的国家里都不够卖！这玩意儿跟消费品逻辑挺像，供给决定需求，一旦获批，供给一跟上，销量肯定能跟着往上冲，到时候特许权使用费也得跟着涨","plainDigest":"$励晶太平洋(00575)$ 现在这药在欧洲已经获批的国家里都不够卖！这玩意儿跟消费品逻辑挺像，供给决定需求，一旦获批，供给一跟上，销量肯定能跟着往上冲，到时候特许权使用费也得跟着涨","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1774887817699,"gmtModify":1774887819821,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":47,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/548308016691176","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":165,"displayRows":4,"foldSize":0,"authorId":"4163739437225380"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.530551108388384","cardData":[{"tweetId":"530551108388384","author":{"authorId":"4233652636908790","idStr":"4233652636908790","name":"大风车吹吹","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 现在的年轻群体对男性健康问题一点不避讳，认知上来了，主动关注和用药的人自然越来越多，再加上线上购药越来越普及，隐私性好还方便，正规处方药慢慢把乱七八糟的偏方和不合规产品挤出去是板上钉钉的事，手里有海外获批成熟品种的公司，天然就有合规和临床数据的硬壁垒 <a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a><a href=\"https://laohu8.com/S/600196\">$复星医药(600196)$ </a> <a href=\"https://laohu8.com/S/301263\">$泰恩康(301263)$ </a> ","plainDigest":"$励晶太平洋(00575)$ 现在的年轻群体对男性健康问题一点不避讳，认知上来了，主动关注和用药的人自然越来越多，再加上线上购药越来越普及，隐私性好还方便，正规处方药慢慢把乱七八糟的偏方和不合规产品挤出去是板上钉钉的事，手里有海外获批成熟品种的公司，天然就有合规和临床数据的硬壁垒 $励晶太平洋(00575)$ $复星医药(600196)$ $泰恩康(301263)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770550033078,"gmtModify":1770550428851,"symbols":["301263","00575","600196","02196"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":792,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/530551108388384","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":315,"displayRows":4,"foldSize":0,"authorId":"4233652636908790"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.530483523748304","cardData":[{"tweetId":"530483523748304","author":{"authorId":"4231334555533442","idStr":"4231334555533442","name":"肯帕杜听了吗","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 长寿科技赛道已从概念走向实质落地，毕马威数据显示2035年中国抗衰老产业规模将触及4.6万亿元，2024-2035年复合增速19.8%，是整体医疗健康增速的3.9倍。高净值人群前置健康投资需求持续爆发，调研显示超33.8%的高净值人群主动增加抗衰与健康管理支出，定制化延寿服务与AI量化评估成为两大核心增长点。<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> <a href=\"https://laohu8.com/S/00767\">$中基长寿科学(00767)$ </a> <a href=\"https://laohu8.com/S/300261\">$雅本化学(300261)$ </a>","plainDigest":"$励晶太平洋(00575)$ 长寿科技赛道已从概念走向实质落地，毕马威数据显示2035年中国抗衰老产业规模将触及4.6万亿元，2024-2035年复合增速19.8%，是整体医疗健康增速的3.9倍。高净值人群前置健康投资需求持续爆发，调研显示超33.8%的高净值人群主动增加抗衰与健康管理支出，定制化延寿服务与AI量化评估成为两大核心增长点。$励晶太平洋(00575)$ $中基长寿科学(00767)$ $雅本化学(300261)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770533551591,"gmtModify":1770538501503,"symbols":["00767","00575","300261"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":820,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/530483523748304","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":349,"displayRows":4,"foldSize":0,"authorId":"4231334555533442"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.530205880874448","cardData":[{"tweetId":"530205880874448","author":{"authorId":"4233471011907460","idStr":"4233471011907460","name":"锦龙","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 国家级专精特新“小巨人”康诺生物冲刺港股！以线粒体医学为核心，搭建“检测-干预-再检测”完整闭环，核心产品占营收半壁江山，两款管线进入临床二期，叠加抗衰赛道高景气，成长逻辑清晰可落地 <a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> <a href=\"https://laohu8.com/S/01093\">$石药集团(01093)$ </a> ","plainDigest":"$励晶太平洋(00575)$ 国家级专精特新“小巨人”康诺生物冲刺港股！以线粒体医学为核心，搭建“检测-干预-再检测”完整闭环，核心产品占营收半壁江山，两款管线进入临床二期，叠加抗衰赛道高景气，成长逻辑清晰可落地 $励晶太平洋(00575)$ $石药集团(01093)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770465691083,"gmtModify":1770468806030,"symbols":["00575","01093"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":836,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/530205880874448","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":225,"displayRows":4,"foldSize":0,"authorId":"4233471011907460"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.530090900432368","cardData":[{"tweetId":"530090900432368","author":{"authorId":"4233490409907660","idStr":"4233490409907660","name":"一共是","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 低估值、有实控业务、有催化节点的标的值得高看一眼，<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 的药品业务托底、AI 长寿业务提估值， <a href=\"https://laohu8.com/S/00767\">$中基长寿科学(00767)$ </a> 的服务端稳需求，两个都属于被情绪低估的品种。$平安好医生$ 回调到位，$阿里健康$还行吧，再跟进看看","plainDigest":"$励晶太平洋(00575)$ 低估值、有实控业务、有催化节点的标的值得高看一眼，$励晶太平洋(00575)$ 的药品业务托底、AI 长寿业务提估值， $中基长寿科学(00767)$ 的服务端稳需求，两个都属于被情绪低估的品种。$平安好医生$ 回调到位，$阿里健康$还行吧，再跟进看看","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770437646604,"gmtModify":1770439761706,"symbols":["00767","00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":1,"viewCount":585,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/530090900432368","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":228,"displayRows":4,"foldSize":0,"authorId":"4233490409907660"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.530134716408968","cardData":[{"tweetId":"530134716408968","author":{"authorId":"4231336543884380","idStr":"4231336543884380","name":"落叶松有空","avatar":"https://static.tigerbbs.com/default-avatar2.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/00575\">$励晶太平洋(00575)$ </a> 的Senstend(Fortacin)早已在欧洲多国获批商业化，外用早泄喷剂赛道海外布局成熟！现在复星万邦助力冲刺中国市场，国内5500万20-59岁男性早泄潜在患者、首年900万潜在用户，空间远超海外。700万确定性里程碑付款更是业绩安全垫，估值修复逻辑硬得很！","plainDigest":"$励晶太平洋(00575)$ 的Senstend(Fortacin)早已在欧洲多国获批商业化，外用早泄喷剂赛道海外布局成熟！现在复星万邦助力冲刺中国市场，国内5500万20-59岁男性早泄潜在患者、首年900万潜在用户，空间远超海外。700万确定性里程碑付款更是业绩安全垫，估值修复逻辑硬得很！","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1770448309429,"gmtModify":1770455595395,"symbols":["00575"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":780,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/530134716408968","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":242,"displayRows":4,"foldSize":0,"authorId":"4231336543884380"}],"position":0}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20893540","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5QjVNt5jXq","pdf_url":"https://static.tigerbbs.com/ccc601b8ccca4ed0b6d0e32289141712","pub_time":1774533600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至二零二五年十二月三十一日止年度之经审核末期业绩","symbol":"00575","title":"截至二零二五年十二月三十一日止年度之经审核末期业绩","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0326/2026032602499_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 核数师发出“非标准报告”]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-03-26 22:00","pubTimestamp":1774533600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20190649","market":"hk","labels":[],"media":"港交所","original_id":"N.HK2m2XKo5nru","pdf_url":"https://static.tigerbbs.com/ab9e7f52e5e14266866ae4d4f087603c","pub_time":1758530880000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025中期报告","symbol":"00575","title":"2025中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0922/2025092200557_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-22 16:48","pubTimestamp":1758530880,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20068763","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9sXXFC74H8","pdf_url":"https://static.tigerbbs.com/9b7b1e8d76a542db827790b58510028c","pub_time":1756289340000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至二零二五年六月三十日止六个月之未经审核中期业绩","symbol":"00575","title":"截至二零二五年六月三十日止六个月之未经审核中期业绩","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0827/2025082701122_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-27 18:09","pubTimestamp":1756289340,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19805615","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7ErrL87vGj","pdf_url":"https://static.tigerbbs.com/3001448180e846d9926e2022d19e17cd","pub_time":1750844040000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"完成关连交易 - 涉及根据特别授权发行新股份之贷款资本化","symbol":"00575","title":"完成关连交易 - 涉及根据特别授权发行新股份之贷款资本化","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0625/2025062500855_c.pdf","us_notice_code":"公告及通告 - [关连交易 / 根据特定授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-06-25 17:34","pubTimestamp":1750844040,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19646284","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEANTCATdyJ","pdf_url":"https://static.tigerbbs.com/61a348ccd053437593a669cdababfb68","pub_time":1747299300000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"(1)关连交易 - 涉及根据特别授权发行新股份之贷款资本化及(2)股东特别大会通告","symbol":"00575","title":"(1)关连交易 - 涉及根据特别授权发行新股份之贷款资本化及(2)股东特别大会通告","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0515/2025051500538_c.pdf","us_notice_code":"通函 - [关连交易 / 发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-05-15 16:55","pubTimestamp":1747299300,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19532746","market":"hk","labels":[],"media":"港交所","original_id":"N.HK3yvzZYJTTs","pdf_url":"https://static.tigerbbs.com/d440cb205f91443f8dafba00847f24c2","pub_time":1745834880000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"(1)建议发行股份及回购股份之一般授权；(2)重选退任董事；及(3)股东周年大会通告","symbol":"00575","title":"(1)建议发行股份及回购股份之一般授权；(2)重选退任董事；及(3)股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042802711_c.pdf","us_notice_code":"通函 - [一般性授权 / 回购股份的说明函件 / 在股东批准的情况下重选或委任董事]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2025-04-28 18:08","pubTimestamp":1745834880,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19532718","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDU7aMDjoGk","pdf_url":"https://static.tigerbbs.com/4a0c9ca191484eed9f16870bdd938913","pub_time":1745834760000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024年年报","symbol":"00575","title":"2024年年报","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0428/2025042802697_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报 / 环境、社会及管治资料/报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-28 18:06","pubTimestamp":1745834760,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19356926","market":"hk","labels":[],"media":"港交所","original_id":"N.HK3V4VGWWx1d","pdf_url":"https://static.tigerbbs.com/815cc49936304babbffc300c60e6b264","pub_time":1744030020000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"关连交易 - 涉及根据特别授权发行新股份之贷款资本化","symbol":"00575","title":"关连交易 - 涉及根据特别授权发行新股份之贷款资本化","titleType":"股份发行","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0407/2025040702240_c.pdf","us_notice_code":"公告及通告 - [关连交易 / 根据特定授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Issuance","event_type":"important_notice","event_name":"股份发行","pubTime":"2025-04-07 20:47","pubTimestamp":1744030020,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19298944","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGrepoxBXds","pdf_url":"https://static.tigerbbs.com/a4b4550d53f94f3983afb3876fcee5aa","pub_time":1743085080000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至二零二四年十二月三十一日止年度之经审核末期业绩","symbol":"00575","title":"截至二零二四年十二月三十一日止年度之经审核末期业绩","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0327/2025032702580_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 核数师发出“非标准报告”]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-27 22:18","pubTimestamp":1743085080,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19094288","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDs5FsfAUBu","pdf_url":"https://static.tigerbbs.com/14ea9b85fcfe4f17a60119c36cd17193","pub_time":1738659420000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至二零二四年十二月三十一日止年度之业绩预告","symbol":"00575","title":"截至二零二四年十二月三十一日止年度之业绩预告","titleType":"业绩预告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0204/2025020400946_c.pdf","us_notice_code":"公告及通告 - [盈利警告 / 内幕消息]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Earnings Estimation","event_type":"important_notice","event_name":"业绩预告","pubTime":"2025-02-04 16:57","pubTimestamp":1738659420,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18636708","market":"hk","labels":[],"media":"港交所","original_id":"N.HKBiGwHsZMpp","pdf_url":"https://static.tigerbbs.com/249e6eb92076481898b9714c15fea5a6","pub_time":1727080380000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024中期报告","symbol":"00575","title":"2024中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0923/2024092300467_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-23 16:33","pubTimestamp":1727080380,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18541271","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4QPdXjJdVJ","pdf_url":"https://static.tigerbbs.com/fc58108881904b7a8442ade1f6ab472d","pub_time":1724852400000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至二零二四年六月三十日止六个月之未经审核中期业绩","symbol":"00575","title":"截至二零二四年六月三十日止六个月之未经审核中期业绩","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0828/2024082801910_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-28 21:40","pubTimestamp":1724852400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18400664","market":"hk","labels":[],"media":"港交所","original_id":"N.HKS36qztBL8z","pdf_url":"https://static.tigerbbs.com/9e4b917c121b46cc801b414d5e560849","pub_time":1721898300000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"二零二四年半年度业绩预告","symbol":"00575","title":"二零二四年半年度业绩预告","titleType":"业绩预告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0725/2024072500710_c.pdf","us_notice_code":"公告及通告 - [盈利警告 / 内幕消息]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Earnings Estimation","event_type":"important_notice","event_name":"业绩预告","pubTime":"2024-07-25 17:05","pubTimestamp":1721898300,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18334045","market":"hk","labels":[],"media":"港交所","original_id":"N.HKH3ukLa3LoL","pdf_url":"https://static.tigerbbs.com/dc36789618b44377a1ec477b3e41ba42","pub_time":1719914220000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"终止有关出售目标公司之25%股权之须予披露交易","symbol":"00575","title":"终止有关出售目标公司之25%股权之须予披露交易","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0702/2024070202763_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 终止交易 / 内幕消息]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2024-07-02 17:57","pubTimestamp":1719914220,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18270700","market":"hk","labels":[],"media":"港交所","original_id":"N.HK6HC3LQqcKu","pdf_url":"https://static.tigerbbs.com/49275aeeba2146f2b685dbf701c40331","pub_time":1718356920000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 出售上市证券","symbol":"00575","title":"须予披露交易 - 出售上市证券","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0614/2024061400658_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2024-06-14 17:22","pubTimestamp":1718356920,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.Regentpac.com","stockEarnings":[{"period":"1week","weight":-0.125},{"period":"1month","weight":-0.2222},{"period":"3month","weight":-0.3204},{"period":"6month","weight":-0.0789},{"period":"1year","weight":0.6867},{"period":"ytd","weight":-0.3458}],"compareEarnings":[{"period":"1week","weight":0.0105},{"period":"1month","weight":-0.0253},{"period":"3month","weight":-0.0464},{"period":"6month","weight":-0.0746},{"period":"1year","weight":0.0825},{"period":"ytd","weight":-0.0201}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"励晶太平洋集团有限公司（原名：寿康集团有限公司）是一家主要从事生物医药及投资业务的投资控股公司。该公司通过两个分部运营业务。生物医药分部主要从事生物医药产品的研究、开发、制造、推广及销售业务。企业投资分部主要从事上市及非上市公司投资业务。该公司还从事衰老研究及开发衰老研究相关的人工智能模型和工具产品。其向长寿诊所、预防医学组织、健康俱乐部、保险公司和老化研究机构提供老化和长寿时钟。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":0.013636},{"month":2,"riseRate":0.482759,"avgChangeRate":0.025922},{"month":3,"riseRate":0.275862,"avgChangeRate":-0.054908},{"month":4,"riseRate":0.517241,"avgChangeRate":0.096459},{"month":5,"riseRate":0.535714,"avgChangeRate":0.06981},{"month":6,"riseRate":0.344828,"avgChangeRate":-0.024692},{"month":7,"riseRate":0.310345,"avgChangeRate":-0.017778},{"month":8,"riseRate":0.413793,"avgChangeRate":-0.03769},{"month":9,"riseRate":0.344828,"avgChangeRate":-0.039055},{"month":10,"riseRate":0.482759,"avgChangeRate":0.048501},{"month":11,"riseRate":0.482759,"avgChangeRate":0.035531},{"month":12,"riseRate":0.448276,"avgChangeRate":0.011323}],"exchange":"SEHK","name":"励晶太平洋","nameEN":"REGENT PACIFIC"},"aProfile":null}}}